Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YELLOW III: Evolocumab on Coronary Plaque
NCT04710368Phase 4Completed
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in coronary artery disease (CAD). Started May 2021; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04710368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710368.